Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 7, 2000, Pages 2476-2482

  Biermasz, Nienke R ^a   Van Dulken, Hans ^a   Roelfsema, Ferdinand ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GLUCOSE TOLERANCE TEST; GROWTH HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

EID: 0034458010     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.85.7.6699     Document Type: Article

References (48)

1. Radiation therapy of acromegaly
2. How effective is external pituitary irradiation for growth hormone-secreting pituitary tumors?
3. Treatment of acromegaly by external irradiation
4. Growth hormone producing pituitary adenomas with concomitant hypersecretion of prolactin are particularly sensitive to photon irradiation
5. Conventional supervoltage radiation in the treatment of acromegaly
6. New developments in the management of acromegaly. Should we achieve absolute biochemical cure?
7. Megavoltage pituitary irradiation lowers but seldom leads to safe GH levels in acromegaly: A long-term follow-up study
8. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly
9. The Birmingham pituitary database: Auditing the outcome of the treatment of acromegaly
10. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure
11. Factors determining the long-term outcome of surgery for acromegaly
12. The outcome of surgery for acromegaly: The need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma
13. Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly
14. A low starting dose of genotropin in growth hormone-deficient adults
15. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly
16. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initial outcome and long-term results
17. Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: Outcome analysis and determinants of failure
18. Results of surgical treatment for growth hormone-secreting pituitary adenomas
19. Long-term results of transsphenoidal pituitary microsurgery in 60 acromegalic patients
20. Treatment of acromegaly with B2036-PEG, a growth hormone receptor antagonist
21. Sandostatin LAR: A promising therapeutic tool in the management of acromegalic patients
22. Hormonal and radiological effects of megavoltage radiotherapy in patients with growth hormone-secreting pituitary adenoma
23. Outcome of radiotherapy for acromegaIy using normalization of IGF-I level to define cure
24. Efficacy of radiotherapy in normalizing IGF-I levels in acromegalic patients
25. The role of radiotherapy in acromegaly
26. Long-term endocrinologicaI follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly
27. The effectiveness of external beam radiotherapy for acromegaly is not affected by previous pituitary ablative treatments
28. Low-dose pituitary irradiation for acromegaly
29. Transsphenoidal microsurgicaI treatment of acromegaly
30. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly
31. A comparison of different methods for diagnosing acromegaly
32. Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1
33. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly
34. Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly
35. Inter-relations between growth hormone, insulin, insulin-like growth factor-I (IGF-I), IGF-binding protein-1 (IGFBP-1) and sex hormone-binding globulin in acromegaly
36. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: Correlation with the degree of growth hormone hypersecretion
37. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion
38. Evaluation of disease activity by IGF-I and IGF binding protein-3 (IGFBP3) in acromegaly patients distributed according to a clinical score
39. Long-term effects of radiotherapy for acromegaly on circulating prolactin
40. Transsphenoidal microsurgical removal of growth hormone-secreting pituitary adenomas. A review of 137 cases
41. Radiation-induced hypopituitarism is dose-dependent
42. Treatment of chromofobe adenomas of the pituitary gland and acromegaly
43. Conventional supervoltage irradiation is an effective treatment for acromegaly
44. Diagnosis of growth-hormone deficiency in adults
45. Stereotactic radiosurgery for recurrent surgically treated acromegaly: Comparison with fractionated radiotherapy
46. Stereotactic radiosurgery in pituitary adenomas
47. Efficacy of gamma-knife radiosurgery in the treatment of pituitary tumors
48. Gamma-knife surgery for secreting pituitary adenomas